Genmab — Maj 2025
-
C25-regnskaber, 1. kvartal 2025: Karakterbogen https://proinvestor.com/boards/126363
-
Genmab to Present New and Updated Results from its Robust Epcoritamab (EPKINLY
) Development Program at the 2025 European Hematology Association (EHA) Congress https://ir.genmab.com/news-releases/news-release-details/genmab-present-new-and-updated-results-its-robust-epcoritamab -
Investeringspodcasten 274: Status på de danske aktier https://proinvestor.com/boards/126364
-
Genmab: 14.33
-
maybe i should post the link for the more
lazy people https://library.ehaweb.org/eha/#!*search=epcoritamab*browseby=8*listing=0*sortby=1 -
Til sammenligning til EPCORE NHL-2: Background:
First-line (1L) standard of care (SOC) for diffuse large B-cell lymphoma (DLBCL) is rituximab plus C, H, vincristine, and P (R-CHOP), and it continues to evolve with pola-R-CHP showing higher complete response rates (CRR) of 78% and longer progression-free survival (PFS) than R-CHOP (Tilly 2022) -
As said by EL - JNJ nightmare: https://finance.yahoo.com/news/halozyme-j-j-slide-analyst-150056315.html
-
Nu kommer deres lobbyister på overarbejde...
-
Healthcare worst-performing S&P 500 subsector year to date: Mizuho expert
Tariffs, executive orders, and FTC probes are just some of the problems piling up for the pharmaceutical industry. Trump's actions are pressuring a historically "safe" sector.
Yahoo Finance (finance.yahoo.com)
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind